FASN and glioma: Importantly, the biological behavior, metabolic phenotype, and ultimately, the drug sensitivity of gliomas appear to vary with the specific fusion partners (e.g., TACC3 vs. FASN), underscoring the necessity of comprehensive genomic profiling at both diagnosis and recurrence to optimize FGFR-targeted strategies.